Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug…
eTurboNews raksti ir paredzēti tikai abonentiem. Abonements ir BEZMAKSAS.
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
Abonenti piesakās šeit Noklikšķiniet šeit, lai abonētu BEZMAKSAS
KAS IZŅEMT NO ŠĪ RAKSTA:
- Direct Biologics is the first and only EV company to receive FDA Phase 3 approval for an Investigational New Drug….
- Direct Biologics announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.
- eTurboNews raksti ir paredzēti tikai abonentiem.
